GlassScriptPhysician profile
Joseph Adu
NPI 1669965067
$1,982.72
in general payments reported to CMS, 2019-2025
24 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $543 · 2023: $373 · 2024: $408 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $429.42 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $255.36 | 2021-2025 | Lo Loestrin Fe, Orilissa |
| Organon LLC | $182.08 | 2021-2025 | Nexplanon |
| Sage Therapeutics, LLC | $156.43 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $130.92 | 2021-2024 | Ova1 |
| Exeltis, USA INC. | $107.57 | 2022-2024 | Slynd |
| Therapeuticsmd, INC. | $89.72 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $71.98 | 2024-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $69.08 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $67.73 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $64.32 | 2022-2024 | |
| Ethicon US, LLC | $58.66 | 2024 | Enseal X1, Ethicon |
| Avion Pharmaceuticals | $51.12 | 2021-2022 | |
| Myovant Sciences INC. | $36.87 | 2021 | |
| Merck Sharp & Dohme LLC | $27.02 | 2025 | Gardasil 9 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.70 | 2025 | |
| Minerva Surgical, INC | $26.24 | 2021-2022 | |
| Heron Therapeutics, INC. | $22.96 | 2023 | Zynrelef |
| Hologic Sales and Service, LLC | $22.26 | 2021 | |
| Agile Therapeutics, INC. | $19.55 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.88 | 2022 | |
| Evofem Biosciences, INC. | $18.07 | 2022 | |
| Millicent US INC | $16.51 | 2024 | Intrarosa, Femring |
| Coopersurgical, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Adu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.